Table 4 Parkinsonism in the valproate group (n = 59).
| UPDRS >10 (n = 6)* | UPDRS <10 (n = 53)* | p Value | |
|---|---|---|---|
| Age at seizure diagnosis (years) | 23.7 (19.4; 0–53) | 19.1 (13.23; 29–67) | 0.453 |
| Duration on valproate (years) | 7.8 (6.2; 2–17) | 6.79 (5; 1–26) | 0.639 |
| Dose of valproate (mg) | 1425 (354.6) | 1209.9 (555.1) | 0.359 |
| UPDRS | 15.5 | 1 | <0.001 |
| Age, years | 43.5 | 37 | 0.195 |
| Polypharmacy (⩾2 drugs) | 50% | 66.0% | 0.406 |
| Sex | 0.671 | ||
| Male | 2 | 27 | |
| Female | 4 | 26 |
Values are mean (SD; range), mean (SD) or median.
UPDRS, Unified Parkinson's Disease Rating Scale.
*UPDRS: modified UPDRS III (all items of UPDRS III were assessed, but only the most involved hemibody (upper and lower limbs) was recorded for items 20, 21, 22, 23, 24, 25 and 26 for a total maximum score of 56).